Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging

Journal of Controlled Release

Volumn 182, Issue 1, 2014, Pages 83-89

  Theek, Benjamin ^a   Gremse, Felix ^a   Kunjachan, Sijumon ^a   Fokong, Stanley ^a   Pola, Robert ^b   Pechar, Michal ^b   Deckers, Roel ^c   Storm, Gert ^d,e   Ehling, Josef ^a   Kiessling, Fabian ^a   Lammers, Twan ^a,d,e  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Cancer; Drug targeting; EPR; HPMA; Nanomedicine; Theranostics

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DRUG DELIVERY; DRUG DOSAGE; FLUORESCENCE; FLUOROPHORES; MEDICAL NANOTECHNOLOGY; PARAMAGNETIC RESONANCE; POLYMERS; TOMOGRAPHY; ULTRASONIC IMAGING;

CANCER; CORRELATION COEFFICIENT; DRUG-TARGETING; ENHANCED PERMEABILITY AND RETENTION EFFECTS; FLUORESCENCE MOLECULAR TOMOGRAPHY; HPMA; POLYMERIC DRUG CARRIERS; THERANOSTICS;

TUMORS;

DRUG CARRIER; N (2 HYDROXYPROPYL) METHACRYLAMIDE; POLYMER; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; CONTRAST MEDIUM; ENBUCRILATE;

ANALYTIC METHOD; ANALYTICAL PARAMETERS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTED TOMOGRAPHY FLUORESCENCE MOLECULAR TOMOGRAPHY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED FUNCTIONAL ULTRASOUND; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DRUG TARGETING; ENHANCED PERMEABILITY AND RETENTION; FLUORESCENCE IMAGING; FLUORESCENCE MOLECULAR TOMOGRAPHY; IMAGE ANALYSIS; LIMIT OF QUANTITATION; MICRO-COMPUTED TOMOGRAPHY; MICROBUBBLE; MOUSE; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; THREE DIMESIONAL B MODE IMAGING; TOMOGRAPHY; TUMOR VASCULARIZATION; TWO DIMENSIONAL MAXIMUM INTENSITY OVER TIME; ULTRASOUND; ANIMAL; BLOOD FLOW; BLOOD VOLUME; DRUG DELIVERY SYSTEM; ECHOGRAPHY; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOPHYSIOLOGY; PERMEABILITY; PROCEDURES; TUMOR CELL LINE; VASCULARIZATION;

ACRYLAMIDES; ANIMALS; BLOOD VOLUME; CELL LINE, TUMOR; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; ENBUCRILATE; MICE, NUDE; MICROBUBBLES; NEOPLASMS; PERMEABILITY; REGIONAL BLOOD FLOW; TOMOGRAPHY;

EID: 84897452273     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.03.007     Document Type: Article

References (49)

1. V. Wagner, A. Dullaart, A.K. Bock, and A. Zweck The emerging nanomedicine landscape Nat. Biotechnol. 24 2006 1211 1217 (Pubitemid 44564760)
2. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760 (Pubitemid 350223348)
3. T. Lammers, W.E. Hennink, and G. Storm Tumour-targeted nanomedicines: principles and practice Br. J. Cancer 99 2008 392 397
4. B.Y. Kim, J.T. Rutka, and W.C. Chan Nanomedicine N. Engl. J. Med. 363 2010 2434 2443
5. R. Duncan, and R. Gaspar Nanomedicine(s) under the microscope Mol. Pharm. 8 2011 2101 2141
6. T.M. Allen, and P.R. Cullis Liposomal drug delivery systems: from concept to clinical applications Adv. Drug Deliv. Rev. 65 2013 36 48
7. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
8. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71 79
9. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 2010 653 664
10. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
11. S. Taurin, H. Nehoff, and K. Greish Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J. Control. Release 164 2012 265 275
12. I.K. Kwon, S.C. Lee, B. Han, and K. Park Analysis on the current status of targeted drug delivery to tumors J. Control. Release 164 2012 108 114
13. Y.H. Bae, and K. Park Targeted drug delivery to tumors: myths, reality and possibility J. Control. Release 153 2011 198 205
14. T. Lammers SMART drug delivery systems: Back to the future vs. clinical reality Int. J. Pharm. 454 2013 527 529
15. J. Kopecek, and P. Kopeckova HPMA copolymers: origins, early developments, present, and future Adv. Drug Deliv. Rev. 62 2010 122 149
16. T. Lammers, and K. Ulbrich HPMA copolymers: 30 years of advances Adv. Drug Deliv. Rev. 62 2010 119 121
17. H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjug. Chem. 21 2010 797 802
18. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A.H. Thomson, L.S. Murray, T.E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, and J. Cassidy Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee Clin. Cancer Res. 5 1999 83 94 (Pubitemid 29045181)
19. K.J. Harrington, S. Mohammadtaghi, P.S. Uster, D. Glass, A.M. Peters, R.G. Vile, and J.S. Stewart Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes Clin. Cancer Res. 7 2001 243 254 (Pubitemid 32183025)
20. D.J. Crommelin, and A.T. Florence Towards more effective advanced drug delivery systems Int. J. Pharm. 454 2013 496 511
21. L.W. Seymour, D.R. Ferry, D.J. Kerr, D. Rea, M. Whitlock, R. Poyner, C. Boivin, S. Hesslewood, C. Twelves, R. Blackie, A. Schatzlein, D. Jodrell, D. Bissett, H. Calvert, M. Lind, A. Robbins, S. Burtles, R. Duncan, and J. Cassidy Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer Int. J. Oncol. 34 2009 1629 1636
22. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701 (Pubitemid 44286001)
23. R. Duncan Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt Adv. Drug Deliv. Rev. 61 2009 1131 1148
24. L.W. Seymour, D.R. Ferry, D. Anderson, S. Hesslewood, P.J. Julyan, R. Poyner, J. Doran, A.M. Young, S. Burtles, and D.J. Kerr Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin J. Clin. Oncol. 20 2002 1668 1676 (Pubitemid 34260549)
25. F. Kiessling, M. Heilmann, T. Lammers, K. Ulbrich, V. Subr, P. Peschke, B. Waengler, W. Mier, H.H. Schrenk, M. Bock, L. Schad, and W. Semmler Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography Bioconjug. Chem. 17 2006 42 51 (Pubitemid 43157583)
26. T. Lammers, V. Subr, P. Peschke, R. Kuhnlein, W.E. Hennink, K. Ulbrich, F. Kiessling, M. Heilmann, J. Debus, P.E. Huber, and G. Storm Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy Br. J. Cancer 99 2008 900 910
27. Z.R. Lu Molecular imaging of HPMA copolymers: visualizing drug delivery in cell, mouse and man Adv. Drug Deliv. Rev. 62 2010 246 257
28. T. Lammers, V. Subr, K. Ulbrich, W. Hennink, G. Storm, and F. Kiessling Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy NanoToday 5 2010 197 212
29. S. Kunjachan, R. Pola, F. Gremse, B. Theek, J. Ehling, D. Moeckel, B. Hermanns-Sachweh, M. Pechar, K. Ulbrich, W.E. Hennink, G. Storm, W. Lederle, F. Kiessling, and T. Lammers Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines Nano Lett. 14 2014 972 981
30. R.B. Schulz, A. Ale, A. Sarantopoulos, M. Freyer, E. Soehngen, M. Zientkowska, and V. Ntziachristos Hybrid system for simultaneous fluorescence and x-ray computed tomography IEEE Trans. Med. Imaging 29 2010 465 473
31. A. Ale, V. Ermolayev, E. Herzog, C. Cohrs, M.H. de Angelis, and V. Ntziachristos FMT-XCT: in vivo animal studies with hybrid fluorescence molecular tomography-X-ray computed tomography Nat. Methods 9 2012 615 620
32. S. Kunjachan, F. Gremse, B. Theek, P. Koczera, R. Pola, M. Pechar, T. Etrych, K. Ulbrich, G. Storm, F. Kiessling, and T. Lammers Noninvasive optical imaging of nanomedicine biodistribution ACS Nano 7 2013 252 262
33. F. Kiessling, S. Fokong, P. Koczera, W. Lederle, and T. Lammers Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics J. Nucl. Med. 53 2012 345 348
34. J. Ehling, T. Lammers, and F. Kiessling Non-invasive imaging for studying anti-angiogenic therapy effects Thromb. Haemost. 109 2013 375 390
35. S. Fokong, M. Siepmann, Z. Liu, G. Schmitz, F. Kiessling, and J. Gatjens Advanced characterization and refinement of poly N-butyl cyanoacrylate microbubbles for ultrasound imaging Ultrasound Med. Biol. 37 2011 1622 1634
36. J.L. Tremoleda, A. Kerton, and W. Gsell Anaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare EJNMMI Res. 2 2012 44
37. F. Gremse, and V. Schulz Qualitative and Quantitative Data Analysis F. Kiessling, B. Pichler, Small Animal Imaging 2011 Springer Berlin Heidelberg 363 378
38. M. Palmowski, W. Lederle, J. Gaetjens, M. Socher, P. Hauff, J. Bzyl, W. Semmler, R.W. Gunther, and F. Kiessling Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound Eur. J. Radiol. 75 2010 e149 e153
39. A. Rix, W. Lederle, M. Siepmann, S. Fokong, F.F. Behrendt, J. Bzyl, C. Grouls, F. Kiessling, and M. Palmowski Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment Eur. J. Radiol. 81 2012 2710 2716
40. Q. Zhang, H. Yang, S.J. Kang, Y. Wang, G.D. Wang, T. Coulthard, and H.E. Grossniklaus In vivo high-frequency, contrast-enhanced ultrasonography of uveal melanoma in mice: imaging features and histopathologic correlations Invest. Ophthalmol. Vis. Sci. 52 2011 2662 2668
41. K. Licha, and C. Olbrich Optical imaging in drug discovery and diagnostic applications Adv. Drug Deliv. Rev. 57 2005 1087 1108 (Pubitemid 40797571)
42. M. Liong, J. Lu, M. Kovochich, T. Xia, S.G. Ruehm, A.E. Nel, F. Tamanoi, and J.I. Zink Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery ACS Nano 2 2008 889 896
43. J. Gao, K. Chen, R. Luong, D.M. Bouley, H. Mao, T. Qiao, S.S. Gambhir, and Z. Cheng A novel clinically translatable fluorescent nanoparticle for targeted molecular imaging of tumors in living subjects Nano Lett. 12 2012 281 286
44. M.A. Hamburg, and F.S. Collins The path to personalized medicine N. Engl. J. Med. 363 2010 301 304
45. L. Chin, J.N. Andersen, and P.A. Futreal Cancer genomics: from discovery science to personalized medicine Nat. Med. 17 2011 297 303
46. T. Lammers, S. Aime, W.E. Hennink, G. Storm, and F. Kiessling Theranostic nanomedicine Acc. Chem. Res. 44 2011 1029 1038
47. T. Lammers, L.Y. Rizzo, G. Storm, and F. Kiessling Personalized nanomedicine Clin. Cancer Res. 18 2012 4889 4894
48. S. Mura, and P. Couvreur Nanotheranostics for personalized medicine Adv. Drug Deliv. Rev. 64 2012 1394 1416
49. L.Y. Rizzo, B. Theek, G. Storm, F. Kiessling, and T. Lammers Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications Curr. Opin. Biotechnol. 24 2013 1159 1166